Open innovation in new drug research: the Indian perspective

Research output: Contribution to conferencePaper

Abstract

This article sketches open innovation strategies pursued by eight Indian pharmaceutical firms and provides an account of strategic flexibility charted by firms in the wake of changes in the legislative environment. The findings examined through the lens of open innovation and dynamic capabilities identifies ‘technological competencies’ and ‘funding’ as two very important reasons, which push the traditionally closed R&D firms to pursue open innovation. Within the dynamic capabilities framework, the findings suggest that resources and competencies play a vital role in enabling open innovation in the complex new drug research setting.

Conference

Conference22nd EurOMA 2015
CountrySwitzerland
CityNeuchâtel
Period26/06/151/07/15

Fingerprint

Innovation
Drug products
Lenses
Drugs
Open innovation
Competency
Dynamic capabilities

Keywords

  • innovation strategies
  • open innovation
  • dynamic capabilities framework
  • pharmaceutical industry
  • India
  • drug research

Cite this

Bhatnagar, B., Dörfler, V., & MacBryde, J. (2015). Open innovation in new drug research: the Indian perspective. Paper presented at 22nd EurOMA 2015, Neuchâtel, Switzerland.
@conference{23d03506f2d149e5bb9861f00ccc671d,
title = "Open innovation in new drug research: the Indian perspective",
abstract = "This article sketches open innovation strategies pursued by eight Indian pharmaceutical firms and provides an account of strategic flexibility charted by firms in the wake of changes in the legislative environment. The findings examined through the lens of open innovation and dynamic capabilities identifies ‘technological competencies’ and ‘funding’ as two very important reasons, which push the traditionally closed R&D firms to pursue open innovation. Within the dynamic capabilities framework, the findings suggest that resources and competencies play a vital role in enabling open innovation in the complex new drug research setting.",
keywords = "innovation strategies, open innovation, dynamic capabilities framework, pharmaceutical industry, India, drug research",
author = "Bhawani Bhatnagar and Viktor D{\"o}rfler and Jillian MacBryde",
year = "2015",
month = "6",
day = "30",
language = "English",
note = "22nd EurOMA 2015 ; Conference date: 26-06-2015 Through 01-07-2015",

}

Bhatnagar, B, Dörfler, V & MacBryde, J 2015, 'Open innovation in new drug research: the Indian perspective' Paper presented at 22nd EurOMA 2015, Neuchâtel, Switzerland, 26/06/15 - 1/07/15, .

Open innovation in new drug research : the Indian perspective. / Bhatnagar, Bhawani; Dörfler, Viktor; MacBryde, Jillian.

2015. Paper presented at 22nd EurOMA 2015, Neuchâtel, Switzerland.

Research output: Contribution to conferencePaper

TY - CONF

T1 - Open innovation in new drug research

T2 - the Indian perspective

AU - Bhatnagar, Bhawani

AU - Dörfler, Viktor

AU - MacBryde, Jillian

PY - 2015/6/30

Y1 - 2015/6/30

N2 - This article sketches open innovation strategies pursued by eight Indian pharmaceutical firms and provides an account of strategic flexibility charted by firms in the wake of changes in the legislative environment. The findings examined through the lens of open innovation and dynamic capabilities identifies ‘technological competencies’ and ‘funding’ as two very important reasons, which push the traditionally closed R&D firms to pursue open innovation. Within the dynamic capabilities framework, the findings suggest that resources and competencies play a vital role in enabling open innovation in the complex new drug research setting.

AB - This article sketches open innovation strategies pursued by eight Indian pharmaceutical firms and provides an account of strategic flexibility charted by firms in the wake of changes in the legislative environment. The findings examined through the lens of open innovation and dynamic capabilities identifies ‘technological competencies’ and ‘funding’ as two very important reasons, which push the traditionally closed R&D firms to pursue open innovation. Within the dynamic capabilities framework, the findings suggest that resources and competencies play a vital role in enabling open innovation in the complex new drug research setting.

KW - innovation strategies

KW - open innovation

KW - dynamic capabilities framework

KW - pharmaceutical industry

KW - India

KW - drug research

UR - http://www.euroma2015.org/

M3 - Paper

ER -

Bhatnagar B, Dörfler V, MacBryde J. Open innovation in new drug research: the Indian perspective. 2015. Paper presented at 22nd EurOMA 2015, Neuchâtel, Switzerland.